Legislative efforts and a Trump administration initiative could lead in the near future to Medicare beneficiary access to ...

Relief is coming for more than 5 million Medicare beneficiaries who rely on expensive prescription medications.

Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to ...

UBS downgraded its rating of Novo to "neutral" from "buy" and lowered its 12-month price target to 340 Danish krone from 600 Danish krone. Copenhagen-listed shares in Novo, which have slumped by more ...

The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.